SUTRO BIOPHARMA, INC. Comprehensive Income
SUTRO BIOPHARMA, INC. (STRO) reported Comprehensive Income of -$38.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$38.49M.
- SUTRO BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$38.60M.
- SUTRO BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$46.78M.
- SUTRO BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$56.81M.
- SUTRO BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$191.11M.
- SUTRO BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$227.44M.
- SUTRO BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$106.15M.
- SUTRO BIOPHARMA, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$119.51M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$38.49M 10-Q · filed 2026-08-12 | -$77.09M 10-Q · filed 2026-08-12 | -$123.87M derived: sum of 3 quarters · filed 2026-08-12 | -$180.68M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$38.60M 10-Q · filed 2026-05-14 | -$85.38M derived: sum of 2 quarters · filed 2026-05-14 | -$142.19M derived: sum of 3 quarters · filed 2026-05-14 | -$153.69M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$46.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$103.59M derived: sum of 2 quarters · filed 2026-03-23 | -$115.09M derived: sum of 3 quarters · filed 2026-08-12 | -$191.11M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$56.81M 10-Q · filed 2025-11-06 | -$68.31M derived: sum of 2 quarters · filed 2026-08-12 | -$144.33M 10-Q · filed 2025-11-06 | -$216.84M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$11.50M 10-Q · filed 2026-08-12 | -$87.52M 10-Q · filed 2026-08-12 | -$160.03M derived: sum of 3 quarters · filed 2026-08-12 | -$208.55M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$76.02M 10-Q · filed 2026-05-14 | -$148.53M derived: sum of 2 quarters · filed 2026-05-14 | -$197.04M derived: sum of 3 quarters · filed 2026-05-14 | -$245.11M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$72.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$121.03M derived: sum of 2 quarters · filed 2026-03-23 | -$169.10M derived: sum of 3 quarters · filed 2026-03-23 | -$227.44M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$48.52M 10-Q · filed 2025-11-06 | -$96.59M derived: sum of 2 quarters · filed 2025-11-06 | -$154.93M 10-Q · filed 2025-11-06 | -$123.85M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$48.07M 10-Q · filed 2025-08-07 | -$106.42M 10-Q · filed 2025-08-07 | -$75.34M derived: sum of 3 quarters · filed 2025-08-07 | -$124.63M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$58.35M 10-Q · filed 2025-05-08 | -$27.27M derived: sum of 2 quarters · filed 2025-05-08 | -$76.56M derived: sum of 3 quarters · filed 2025-05-08 | -$114.96M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $31.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$18.21M derived: sum of 2 quarters · filed 2025-03-13 | -$56.62M derived: sum of 3 quarters · filed 2025-03-13 | -$106.15M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$49.29M 10-Q · filed 2024-11-13 | -$87.69M derived: sum of 2 quarters · filed 2024-11-13 | -$137.23M 10-Q · filed 2024-11-13 | -$171.11M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | -$38.40M 10-Q · filed 2024-08-13 | -$87.94M 10-Q · filed 2024-08-13 | -$121.82M derived: sum of 3 quarters · filed 2025-03-13 | -$141.28M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | -$49.54M 10-Q · filed 2024-05-13 | -$83.42M derived: sum of 2 quarters · filed 2025-03-13 | -$102.88M derived: sum of 3 quarters · filed 2025-03-13 | -$129.10M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | -$33.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$53.34M derived: sum of 2 quarters · filed 2025-03-13 | -$79.56M derived: sum of 3 quarters · filed 2025-03-13 | -$119.51M 10-K · filed 2025-03-13 |
| 2022-09-30 | -$19.47M 10-Q · filed 2023-11-13 | -$45.68M derived: sum of 2 quarters · filed 2023-11-13 | -$85.63M 10-Q · filed 2023-11-13 | -$124.04M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | -$26.22M 10-Q · filed 2023-08-10 | -$66.16M 10-Q · filed 2023-08-10 | -$104.57M derived: sum of 3 quarters · filed 2024-03-25 | -$135.46M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | -$39.95M 10-Q · filed 2023-05-15 | -$78.36M derived: sum of 2 quarters · filed 2024-03-25 | -$109.24M derived: sum of 3 quarters · filed 2024-03-25 | -$115.44M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | -$38.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$69.30M derived: sum of 2 quarters · filed 2024-03-25 | -$75.49M derived: sum of 3 quarters · filed 2024-03-25 | -$105.98M 10-K · filed 2024-03-25 |
| 2021-09-30 | -$30.89M 10-Q · filed 2022-11-08 | -$37.08M derived: sum of 2 quarters · filed 2022-11-08 | -$67.57M 10-Q · filed 2022-11-08 | -$127.22M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | -$6.20M 10-Q · filed 2022-08-08 | -$36.69M 10-Q · filed 2022-08-08 | -$96.34M derived: sum of 3 quarters · filed 2023-03-30 | -$79.36M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | -$30.49M 10-Q · filed 2022-05-09 | -$90.14M derived: sum of 2 quarters · filed 2023-03-30 | -$73.16M derived: sum of 3 quarters · filed 2023-03-30 | -$42.92M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | -$59.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$42.67M derived: sum of 2 quarters · filed 2023-03-30 | -$12.43M derived: sum of 3 quarters · filed 2023-03-30 | -$32.16M 10-K · filed 2023-03-30 |
| 2020-09-30 | $16.98M 10-Q · filed 2021-11-10 | $47.22M derived: sum of 2 quarters · filed 2021-11-10 | $27.49M 10-Q · filed 2021-11-10 | $12.64M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $30.24M 10-Q · filed 2021-08-09 | $10.51M 10-Q · filed 2021-08-09 | -$4.34M derived: sum of 3 quarters · filed 2022-02-28 | -$17.24M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$19.73M 10-Q · filed 2021-05-07 | -$34.58M derived: sum of 2 quarters · filed 2022-02-28 | -$47.48M derived: sum of 3 quarters · filed 2022-02-28 | -$61.12M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$14.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$27.75M derived: sum of 2 quarters · filed 2022-02-28 | -$41.38M derived: sum of 3 quarters · filed 2022-02-28 | -$55.53M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$12.90M 10-Q · filed 2020-11-05 | -$26.54M derived: sum of 2 quarters · filed 2020-11-05 | -$40.69M 10-Q · filed 2020-11-05 | -$42.20M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | -$13.64M 10-Q · filed 2020-08-06 | -$27.78M 10-Q · filed 2020-08-06 | -$29.30M derived: sum of 3 quarters · filed 2021-03-18 | -$39.56M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | -$14.15M 10-Q · filed 2020-05-11 | -$15.66M derived: sum of 2 quarters · filed 2021-03-18 | -$25.92M derived: sum of 3 quarters · filed 2021-03-18 | -$37.47M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | -$1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$11.78M derived: sum of 2 quarters · filed 2021-03-18 | -$23.32M derived: sum of 3 quarters · filed 2021-03-18 | -$35.36M 10-K · filed 2021-03-18 |
| 2018-09-30 | -$10.26M 10-Q · filed 2019-11-08 | -$21.80M derived: sum of 2 quarters · filed 2019-11-08 | -$33.85M 10-Q · filed 2019-11-08 | -$49.19M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | -$11.54M 10-Q · filed 2019-08-14 | -$23.59M 10-Q · filed 2019-08-14 | -$38.93M derived: sum of 3 quarters · filed 2020-03-16 | -$40.34M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | -$12.05M 10-Q · filed 2019-05-15 | -$27.39M derived: sum of 2 quarters · filed 2020-03-16 | -$28.80M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2017-12-31 | -$15.34M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$16.76M derived: sum of 2 quarters · filed 2020-03-16 | -$19.67M 10-K · filed 2020-03-16 | |
| 2017-09-30 | -$1.41M 10-Q · filed 2018-11-14 | -$4.33M 10-Q · filed 2018-11-14 | ||
| 2016-12-31 | $1.74M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |